Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
Main Authors: | Ye Tian, Xu Huang, Li-Juan Wu, Li Yi, Min Li, Si-Chao Gu, Dong-Jie Guo, Qing-Yuan Zhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2018-01-01
|
Series: | Chinese Medical Journal |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=16;spage=2002;epage=2004;aulast=Tian |
Similar Items
-
Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus
by: Hideo Kato, et al.
Published: (2021-03-01) -
Economic evaluation of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
by: Tazio Vanni -
Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus
by: Adão R. L. Machado, et al. -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy
by: Pletz Mathias W, et al.
Published: (2010-11-01) -
An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
by: Patel DA, et al.
Published: (2014-10-01)